Our vision at Alzheon
We strive to change the standard of care.
We are passionate in developing effective treatments for Alzheimer’s disease and other devastating neurodegenerative disorders.
We are applying innovation to drug development in neurodegeneration by capitalizing on scientific and clinical insights, so we can rapidly and efficiently move towards new therapeutic solutions.
We are committed to improving the lives of patients, their families and caregivers.
We aim to develop breakthrough therapies that can change the lives of patients with neurodegenerative disorders.
Clinical studies
For patients and caregivers
APOLLOE4 Phase 3 study
Phase 3 study in APOE4/4 homozygotes with early Alzheimer’s disease – completed.
Phase 2 biomarker study
Single-arm Phase 2 biomarker study in APOE4 carriers – completed.
Valiltramiprosate/ALZ-801 is an investigational product in clinical development, and its use has not been approved by the FDA or EMA.
Questions about our studies?
We are here to help patients, families and caregivers find the information they need.
